Issue Date: June 23, 2008
Boehringer Ingelheim Will Acquire Actimis
Germany's Boehringer Ingelheim has agreed to acquire Actimis Pharmaceuticals, a privately held biotech company in San Diego. Spun off from Bayer in 2004, Actimis focuses on small-molecule drugs for respiratory, inflammatory, and autoimmune diseases. BI will acquire the company through a structured buyout, purchasing shares according to development milestones reached by Actimis' lead compound, called AP768, for treating asthma. If AP768, now in Phase I clinical trials, successfully advances into Phase III, BI will own 100% of Actimis' shares in a deal totaling $515 million.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society